BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12951755)

  • 1. Vancomycin administration during dialysis with low-flux polysulfone membranes: traditional versus a supplemental dosage regimen.
    Stamatakis MK; Schreiber JM; Slain D; Gunel E
    Am J Health Syst Pharm; 2003 Aug; 60(15):1564-8. PubMed ID: 12951755
    [No Abstract]   [Full Text] [Related]  

  • 2. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease.
    Touchette MA; Patel RV; Anandan JV; Dumler F; Zarowitz BJ
    Am J Kidney Dis; 1995 Sep; 26(3):469-74. PubMed ID: 7645555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.
    Ariano RE; Fine A; Sitar DS; Rexrode S; Zelenitsky SA
    Am J Kidney Dis; 2005 Oct; 46(4):681-7. PubMed ID: 16183423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers.
    Lanese DM; Alfrey PS; Molitoris BA
    Kidney Int; 1989 Jun; 35(6):1409-12. PubMed ID: 2770120
    [No Abstract]   [Full Text] [Related]  

  • 5. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes.
    DeSoi CA; Sahm DF; Umans JG
    Am J Kidney Dis; 1992 Oct; 20(4):354-60. PubMed ID: 1415203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.
    Zoer J; Schrander-van der Meer AM; van Dorp WT
    Pharm World Sci; 1997 Aug; 19(4):191-6. PubMed ID: 9297732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin during the Last Hour of the Hemodialysis Session: A Pharmacokinetic Analysis.
    Ghouti-Terki L; Chasseuil E; Rabot N; Paintaud G; François M; Birmelé B; Darrouzain F; Büchler M; Halimi JM; Ternant D
    Nephron; 2017; 135(4):261-267. PubMed ID: 28152540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
    Mason NA; Neudeck BL; Welage LS; Patel JA; Swartz RD
    Clin Nephrol; 2003 Aug; 60(2):96-104. PubMed ID: 12940611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight-based loading of vancomycin in patients on hemodialysis.
    Brown M; Polisetty R; Gracely EJ; Cuhaci B; Schlecht HP
    Clin Infect Dis; 2011 Jul; 53(2):164-6. PubMed ID: 21690623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Approach to Optimise Therapeutic Vancomycin Dosage in a Haemodialysis Population.
    Gunning H; Taylor G; Smyth A; Mellotte G; Fennell J; Murphy P; Lavin P; Wall C
    Ir Med J; 2016 Oct; 109(9):465. PubMed ID: 28125179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy.
    Barth RH; DeVincenzo N
    Kidney Int; 1996 Sep; 50(3):929-36. PubMed ID: 8872968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear).
    Allawati H; Dallas L; Nair S; Palmer J; Thaikandy S; Hutchison C
    Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32408589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin clearance with high-flux dialysis membranes.
    Anandan JV; Touchette MA
    Int J Artif Organs; 1998 Mar; 21(3):131-3. PubMed ID: 9622110
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple-dose pharmacokinetics of cefpirome in long-term hemodialysis with high-flux membranes.
    Thalhammer F; Schmaldienst S; Elmenyawi I; Atteneder M; Burgmann H; Hollenstein U; Georgopoulos A; Graninger W; Putz D; Rosenkranz AR; Mayer G; Hörl WH; Breyer S
    Clin Pharmacol Ther; 1996 Dec; 60(6):645-50. PubMed ID: 8988066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin dosing in patients on intermittent hemodialysis.
    Vandecasteele SJ; De Vriese AS
    Semin Dial; 2011; 24(1):50-5. PubMed ID: 21338394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis.
    Vandecasteele SJ; De Bacquer D; De Vriese AS
    Clin Infect Dis; 2011 Jul; 53(2):124-9. PubMed ID: 21690618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing vancomycin dosage regimens in relation to high-flux haemodialysis.
    Hui K; Patel K; Nalder M; Nelson C; Buising K; Pedagogos E; Kong DCM; Kirkpatrick CMJ
    J Antimicrob Chemother; 2019 Jan; 74(1):130-134. PubMed ID: 30215721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
    Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
    Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of vancomycin in adult cancer patients.
    Al-Kofide H; Zaghloul I; Al-Naim L
    J Oncol Pharm Pract; 2010 Dec; 16(4):245-50. PubMed ID: 20015925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.